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Abstract
Reduced target attainment ofβ-lactam antibiotics is reported in critically ill patients. However, as target attainment of cefotaxime
in severely ill pediatric sepsis patients may differ from adults due to age-related variation in pharmacokinetics, we aimed to assess
target attainment of cefotaxime in this pilot study using meningococcal septic shock patients as a model for severe sepsis.
Secondary analysis of prospectively collected data from a randomized controlled trial. Children with meningococcal septic shock
(1 month to 18 years) included in this study received cefotaxime 100–150 mg/kg/day as antibiotic treatment. Left-over plasma
samples were analyzed using LC-MS/MS to determine cefotaxime concentrations. MIC values from EUCAST were used to
determine target attainment of cefotaxime for Neisseria meningitidis (0.125 mg/l), but also for Streptococcus pneumoniae
(0.5 mg/l), Enterobacteriaceae (1 mg/l), and Staphylococcus aureus (4 mg/l). Target attainment was adequate when all samples
exceeded MIC or fourfold MIC values. One thirty-six plasma samples of 37 severe septic shock patients were analyzed for
cefotaxime concentrations. Median age was 2 years with a median PRISM-score of 24 and mortality of 24.8%. The median
unbound cefotaxime concentration was 4.8 mg/l (range 0–48.7). Target attainment ranged from 94.6% for the MIC of N.
meningitidis to 16.2% for fourfold the MIC S. aureus. Creatinine levels were significantly correlated with cefotaxime levels.
Target attainment of cefotaxime with current dosing guidelines seems to be adequate for N. meningitidis but seems to fail for
more frequently encountered pathogens in severely ill children.
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Introduction
Studies on the target attainment of β-lactam antibiotics in
critically ill adult patients indicate that up to 41% do not
achieve adequate plasma levels [1]. Pharmacokinetic studies
in critically ill children have shown reduced target attainment
of several, frequently used, antibiotics as well [2–4]. To our
knowledge, only one recent study investigated target attain-
ment of cefotaxime, in a relatively stable PICU cohort [5].
This reduced target attainment is a direct result of patho-
physiological changes during critical illness, causing an in-
crease in the volume of distribution, clearance, or both [6].
The risk of non-target attainment is particularly high for β-
lactam antibiotics, due to their time-dependent kill character-
istics [7].
Meningococcal sepsis is characterized by a severe, rapid
onset of sepsis and multi-organ failure, with a high mortality
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rate (25–30%) and long-term sequelae in 11–19% of survivors
[8]. Although the incidence of meningococcal sepsis has rap-
idly declined due to vaccination for Neisseria meningitidis,
data from these patients can serve as a model for severe sepsis
in critically ill children and guide optimal antibiotic dosing.
The aim of this study was to identify target attainment of
cefotaxime for N. meningitidis in critically ill children with
meningococcal sepsis and to extrapolate to target attainment
for other frequently encountered pathogens in pediatric sepsis.
Materials and methods
Setting
We conducted a secondary analysis of data from a random-
ized, double-blinded, placebo-controlled phase 2 trial (RCT)
designed to assess the activation process of protein C in crit-
ically ill children with meningococcal septic shock [9].
Children were randomized to receive placebo or protein C in
addition to standard care for septic shock including antibiotic
treatment with cefotaxime 100–150 mg/kg/day in 3–4 doses.
Thirty-eight children aged 1 month to 18 years were re-
cruited in the PICU of the Erasmus MC- Sophia Children’s
Hospital, Rotterdam, The Netherlands. The inclusion and ex-
clusion criteria were detailed in the original publication [9].
The RCT had been approved by the Erasmus MC medical
ethics review board and all parents or legal representatives
had signed informed consent for the use of left-over materials
in follow-up research.
Patient characteristics and clinical parameters had been
prospectively collected in the context of the RCT, including
age, weight, gender, disease severity scores (SOFA-score and
PRISM-score), and mortality. Data on antibiotic dosing orders
and co-medication were collected from the hospital records.
Blood samples were taken at PICU admission, 6, 12, and
24 h after admission and once daily thereafter. After analysis
for the RCT, plasma samples were stored at − 80 °C for sec-
ondary use.
Drug analysis
Cefotaxime concentrations in plasma were quantified with a
UPLC–MS/MS system consisting of a Dionex Ultimate
UPLC system connected to a triple quadrupole mass spec-
trometer (Thermo TSQ Vantage with HESI-probe, Thermo
Scientific) [10]. The lower and upper levels of quantification
of this method were 0.13 and 12.5 mg/l, respectively.
Target attainment
β-lactam antibiotics, including cephalosporins like cefotax-
ime, show a time-dependent pathogenic kill potential, with a
pharmacodynamic target of fT>MIC > 60–70%, meaning that
concentrations should be above the MIC for at least 60–70%
of the time [11]. However, recent literature proposes fT>MIC
targets of 100%, associated with better clinical outcome in
critically ill patients [12] and even fT>4xMIC for a maximum
killing potential in critically ill and immunocompromised pa-
tients [13].
Antibiotic plasma concentrations were compared with the
clinical breakpoint for susceptibility of Neisseria meningitidis
to cefotaxime (0.125 mg/l) from the European Committee of
Antimicrobial Susceptibility Testing (EUCAST) [14].
Furthermore, to extrapolate our findings to other infections,
comparisons were made to clinical breakpoints of
Streptococcus pneumoniae (0.5 mg/l), Enterobacteriaceae
(1.0 mg/l), and Staphylococcus aureus (4mg/l), the most com-
mon causative pathogens of pediatric sepsis [15].
Since the RCTwas not designed for cefotaxime PK analysis,
samples were regarded to be randomly scavenged across the
cefotaxime dosing interval. Furthermore, since only total drug
concentrations were determined, we assumed 60% of the total
concentration to be the unbound fraction of cefotaxime [16].
Two approaches to define target attainment were used as
outcome measures: firstly, unbound plasma concentrations
were compared with MIC and fourfold MIC values of the
studied pathogens to define the percentage of samples that
exceeded these target MICs. Secondly, we identified the per-
centage of patients at risk as patients with any unbound cefo-
taxime concentrations below the MIC or fourfold MIC during
their ICU stay.
Statistical analysis
Data were analyzed with IBM SPSS Statistics for Windows,
Version 22.0. Demographic data were analyzed using descrip-
tive statistics and presented as Bmedian (IQR, range)^ for
continuous variables and Babsolute number (percentage)^ for
dichotomous variables.
Linear regression was performed to identify relevant covar-
iates of cefotaxime concentrations (age, PRISM-score, SOFA-
score, and serum creatinine levels). In the cases of multiple
values for a single patient, i.e., for creatinine levels, data were
analyzed using generalized estimating equations (GEE) to cor-
rect for within-patient variation and multiple sampling. In the
case of missing data, values were imputed by linear extrapo-
lation from adjacent data points.
Results
Patient characteristics
A total of 136 plasma samples of 37 out of 38 patients in the
original RCT were available for cefotaxime analysis (1–7
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samples per patient). Patients had a median age of 2 years
(range 0.3–16.1 years) and a median weight of 13.7 kg (range
6–70 kg). Median PRISM scores were 24 (range 4–43) and
the mortality rate during admission was 24.3% (Table 1).
Drug levels and target attainment
Total cefotaxime plasma concentration varied widely, with a
median of 8.0 mg/l (IQR 2.5–18.7 mg/l and range 0–81.1 mg/
l). When accounting for protein binding, median unbound
plasma concentrations were 4.8 mg/l (range 0–48.7 mg/l).
Cefotaxime concentrations were below the lower level of
quantification in six samples, five of which had been taken
at PICU admission (t = 0), in patients having received another
cephalosporin.
The propor t ion of samples above the MIC of
N. meningitides was 95.6% and above the MIC of
S. pneumoniae, Enterobacteriaceae, and S. aureus in 91.2%,
86.0%, and 55.1% of samples, respectively. Using the higher
target (fT>4xMIC), unbound plasma concentrations were
above fourfold MIC of N. meningitidis in 91.2% of samples
and of S. pneumoniae, Enterobacteriaceae, and S. aureus in
71.3%, 55.1%, and 14.7%, respectively (Table 2 and Fig. 1).
The proportion of patients with all of their samples above
the MIC fo r N. men ing i t i d e s , S . pneumon iae ,
Enterobacteriaceae, and S. aureus was 94.6%, 86.5%,
75.7%, and 51.4%, respectively. For the higher target of
fT>4xMIC, this ranged from 86.5% for N. meningitides to
16.2% for S. aureus (Table 3).
Co-variate analysis
The relationships of age, PRISM-score, SOFA-score, and cre-
atinine levels with cefotaxime plasma levels were explored
using linear regression. Of these studied variables, only creat-
inine levels were weakly but significantly correlated with cef-
otaxime levels (R2 = 0.157, p < 0.001), as shown in Fig. 2.
This association was maintained when correcting for repeated
Table 1 Demographic
information of patients Demographic variables All patients (n = 37)
Age (years) 2.0 years
(IQR 0.9–8.3, range 0.3–16.1)
Age groups 0–2 years: 18 (48.6%)
6–12 years: 7 (18.4%)
2–6 years: 10 (26.3%)
12–18 years: 2 (5.3%)
Sex M 21 (56.8%)
F 16 (43.2%)
Weight (kg) 13.7 kg
(IQR 10–30, range 6–70)
PRISM-score 24
(IQR 17–30, range 4–43)
SOFA-score 10
(IQR 8–14, range 4–19)
Mortality n (%) 9/37 (24.3%)
Duration of ICU admission (days)a 4.0 days
(IQR 2.3–7.0, range 1–45)
Cefotaxime dose (mg/kg/day) 150 mg/kg/day
(IQR 150–160, range 133–600)
Receiving more than 1 antibiotic agent
(cefotaxime + rifampicin)
4/37 (10.8%)
Positive culture for Neisseria meningitidis 32/37 (84.2%)
Creatinine levels (μmol/l) b 41 μmol/l
(IQR 24.3–73.8, range 7–462)
a : analysis done on the surviving patients (n = 28),
b : creatinine levels determined by Jaffé method
PRISM predicted risk of mortality score, SOFA sequential organ failure assessment score
Continuous variables are presented as median (IQR, range)
Dichotomous variables are presented as n (%)
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measurements within subjects using GEE (B = 0.061 (95% CI
0.041–0.081, p < 0.001).
Discussion
In this secondary analysis of prospectively collected data, we
evaluated the hypothesis that pathophysiological changes in
critically ill children with sepsis could lead to low target at-
tainment of cefotaxime. To our knowledge, this is the first
cohort of severe pediatric septic shock patients in which cef-
otaxime concentrations are reported.
Although most samples were well above the MIC of
N. meningitidis, even when a higher target of four times the
MIC is pursued, target attainment for less susceptible patho-
gens was poor, even with the most conservative target of
fT>MIC of 100%. Therefore, using cefotaxime in current
doses as blind, broad-spectrum antibiotic therapy might lead
to therapy failure in children with severe sepsis caused by less
susceptible pathogens.
These results are in line with recent population pharmaco-
kinetic studies that show that critically ill children require a
higher dose of β-lactam antibiotics compared with non-
critically ill patients [2–7]. The study by Béranger et al. con-
cludes that the target of fT>MIC 100% is not reached with
standard intermittent cefotaxime dosing in critically ill chil-
dren [5]. An important difference with this population phar-
macokinetic study is that our patients were more severely ill as
is reflected by much higher mortality in our cohort (24.3% vs.
2.0%). Furthermore, kidney function was not included in their
model while in our study creatinine correlated significantly,
albeit weakly, with cefotaxime concentrations. This can be
explained by a greater variation in kidney function in our
cohort (range of creatinine 7–472 μmol/l in our cohort vs.
11–81 μmol/l). However, the large inter-individual variation
in cefotaxime concentrations cannot be contributed to clear-
ance alone, but could be explained by additional changes in
the volume of distribution.
Béranger and colleagues propose continuous dosing to
reach target attainment for patients of any age and weight.
Table 2 Percentage of samples with unbound concentrations above the MIC and fourfold MIC of selected pathogens




































Fig. 1 Plasma concentrations of cefotaxime for each individual patient
with reference lines for the MIC and fourfold MIC of N. meningitidis
(red), S. pneumoniae (green), Enterobacteriaceae (orange), and
S.aureus (blue). The amount of samples and the number of patients
with one or more samples above the MIC or fourfold MIC can be
found in Tables 2 and 3, respectively
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Although continuous infusion is possible on the PICU, it re-
mains cumbersome in routine care. Moreover, meta-analyses
of RCTs in adults are inconclusive whether continuous infu-
sion of β-lactam antibiotics leads to a survival benefit over
intermittent dosing [17, 18].
Our findings suggest that antibiotic dosing guidelines
should incorporate pharmacodynamic endpoints, e.g., MIC
values. Current standard doses result in median unbound plas-
ma concentrations 40-fold above the targeted values for highly
susceptible pathogens like N. meningitidis, but for less sus-
ceptible pathogens even the most conservative target is rarely
reached. Incorporating appropriate pharmacodynamic end-
points in dosing guidelines can offer tailored doses for both
susceptible and less susceptible pathogens. A recent study by
Woksepp et al. investigated target attainment of β-lactam an-
tibiotics in critically ill adults based on theMIC of the cultured
pathogen, compared with EUCAST clinical breakpoints [19].
They found markedly higher target attainment when using the
true-MIC (89%) compared with clinical breakpoints (55%),
which also highlights that data on susceptibility could provide
valuable information to improve antibiotic dosing regimens.
Our study shows some limitations: Firstly, samples were
randomly scavenged and were not collected with the purpose
of evaluating drug disposition. However, since the
pharmacodynamic target for β-lactam antibiotics is to main-
tain drug concentrations above the MIC for the entire dosing
interval, our results represent a Bbest-case scenario^ of target
attainment of cefotaxime for these pathogens in critically ill
children with severe septic shock.
Secondly, samples have been stored for a prolonged period
(maximum 19 years) at – 80 °C and underwent a single freeze-
thaw cycle that could impact sample quality. A study compar-
ing the effect of storage temperature for 11 different β-lactam
antibiotics, including cefotaxime, shows that cefotaxime was
stable after 52 weeks at – 70 °C [20]. In addition, the concen-
trations in our study were similar to those reported in critically
ill adults [21]. Thirdly, we did not determine concentrations of
cefotaxime’s active metabolite desacetyl-cefotaxime, which
does contribute to the antibiotic effect, but we believe it has
limited influence on overall cefotaxime exposure and conse-
quent effect [22].
Conclusion
In this secondary analysis of a prospective RCT, we have
analyzed the target attainment of cefotaxime in critically ill
children. Target attainment of cefotaxime seems adequate for
susceptible pathogens but poor for less susceptible pathogens.
Therefore, using cefotaxime with the current dosing guide-
lines as blind, broad-spectrum antibiotic therapy might lead
to therapy failure. These findings suggest a benefit of incor-
porating pharmacodynamic endpoints in dosing guidelines for
antibiotics. Prospective research is needed for an adequate
analysis of target attainment of cefotaxime in critically ill chil-
dren and identification of relevant covariates to design indi-
vidualized dosing guidelines.
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Fig. 2 Correlation between serum creatinine and unbound plasma
concentrations of cefotaxime. Legend: each dot represents a single
cefotaxime concentration measurement with accessory serum creatinine
concentration. The solid black line represents the linear regression line
(p < 0.001, R2 = 0.157)
Table 3 Percentage of patients with all unbound plasma concentrations above the MIC and fourfold MIC of selected pathogens
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